Nurix Therapeutics Stock Forum

$Nurix Therapeutics (NRIX.US)$
Revolutionary Brain-Penetrant Cancer Drugs Outperform Competitors: 10,000 Proteins Destroyed Per Hour

$Nurix Therapeutics (NRIX.US)$
FDA Green Lights Groundbreaking IRAK4 Degrader: $420M Milestone Potential in Inflammatory Disease Fight

$Nurix Therapeutics (NRIX.US)$ Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025
GS-6791/NX-0479 has potential clinical applications across multiple blockbuster markets in inflammation, in both rheumatology and dermatology, including rheumatoid arthritis and atopic dermatitis
Nurix to receive a $5 million milestone payment from Gilead for FDA clearance of the IND, bringing...

$Nurix Therapeutics (NRIX.US)$ Reuters· 5 mins ago
Nurix Announces FDA Clearance of Ind Application for Gs-6791/Nx-0479 - a Novel Irak4 Degrader for Inflammatory Conditions! Nurix Therapeutics Inc - to Receive $5 Million Milestone Payment From Gilead

$Nurix Therapeutics (NRIX.US)$
Nurix Scores FDA Orphan Drug Win as Q1 Revenue Jumps 11% on Sanofi Deal Success

$Nurix Therapeutics (NRIX.US)$ Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.67) per share which beat the analyst consensus estimate of $(0.78) by 14.1 percent. This is a 11.84 percent increase over losses of $(0.76) per share from the same period last year. The company reported quarterly sales of $18.45 million which beat the analyst consensus estimate of $12.71 million by 45.18 percent. This is a 11.26 percent increase over sales of $16.59 million the same peri...

$Nurix Therapeutics (NRIX.US)$
Revolutionary AI Platform Drives 4 Cancer Drug Innovations: Nurix AACR 2025 Spotlight

$Nurix Therapeutics (NRIX.US)$
Breakthrough: Nurix's Novel Brain-Penetrant Cancer Drug Receives Key FDA Designation

$Nurix Therapeutics (NRIX.US)$
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
Nurix Therapeutics (NRIX) announced that its drug bexobrutideg (NX-5948) has received Orphan Drug Designation (ODD) from the FDA for treating Waldenström macroglobulinemia (WM). Bexobrutideg is an oral, brain-penetrant BTK degrader currently in Phase 1a/b clinical trials for relapsed/refractory B-cell malignancies.
The ODD grants ...

$Nurix Therapeutics (NRIX.US)$ Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
5 MINUTES AGO, 7:00 AM EDT